| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 15, 2025 9:00 A.M. |
| Form: | S-1 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 15, 2025 9:00 A.M. |
| Form: | S-1 | ||||||
| |||||||
Save time and jump to the most important pieces.
SARASOTA, FL, May 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, closed on the previously announced public offering of 3,333,338 shares of common stock (or pre-funded warrants in lieu thereof), together with series A-1 warrants ("Series A-1 Warrants") to purchase up to 3,333,338 shares of common stock and series A-2 warrants ("Series A-2 Warrants") to purchase up to 3,333,338 shares of common stock at a combined public offering price of $0.60 per share (or pre-funded warrant in lieu thereof) and associated Series A-1 Warrant and Series A-2 Warran
SARASOTA, FL, May 15, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the pricing of a public offering of 3,333,338 shares of common stock (or pre-funded warrants in lieu thereof), together with series A-1 warrants ("Series A-1 Warrants") to purchase up to 3,333,338 shares of common stock and series A-2 warrants ("Series A-2 Warrants") to purchase up to 3,333,338 shares of common stock at a combined public offering price of $0.60 per share (or pre-funded warrant in lieu thereof) and associated Series A-1 Warrant and Series A-2 Warrant.
SARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has engaged Veloxity Labs, LLC for bioanalysis supporting the ongoing investigational new drug (IND)-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetics study of its lead asset, SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD). "We look forward to working with Veloxity Labs for GLP sample analysis in our current safety study of SPC-15," said Eric Weisblum, CEO of Silo. "We expect Veloxity to p
4 - Silo Pharma, Inc. (0001514183) (Issuer)
4 - Silo Pharma, Inc. (0001514183) (Issuer)
4 - Silo Pharma, Inc. (0001514183) (Issuer)
8-K - Silo Pharma, Inc. (0001514183) (Filer)
424B4 - Silo Pharma, Inc. (0001514183) (Filer)
EFFECT - Silo Pharma, Inc. (0001514183) (Filer)
SC 13G - Silo Pharma, Inc. (0001514183) (Subject)
SC 13G - Silo Pharma, Inc. (0001514183) (Subject)
SC 13G/A - Silo Pharma, Inc. (0001514183) (Subject)
4 - Silo Pharma, Inc. (0001514183) (Issuer)
4 - Silo Pharma, Inc. (0001514183) (Issuer)
4 - Silo Pharma, Inc. (0001514183) (Issuer)